Repligen to Report Second Quarter 2020 Financial Results
July 15, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30,...
Repligen Announces Agreement to Acquire Engineered Molding Technology
June 29, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into...
Repligen Appoints Carrie Eglinton Manner to Board of Directors
June 15, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of...
Repligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
May 06, 2020 07:30 ET
|
Repligen Corporation
Reports record quarterly revenue of $76.1 millionOverall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months WALTHAM, Mass., May 06, 2020 ...
Repligen to Report First Quarter 2020 Financial Results
April 22, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2020 financial results on Wednesday, May 6, 2020....
Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors
February 27, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of...
Repligen Reports Fourth Quarter and Full Year 2019 Financial Results
February 20, 2020 07:30 ET
|
Repligen Corporation
Reports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year growthOverall organic revenue growth was 21% for...
Repligen to Report Fourth Quarter and Full Year 2019 Financial Results
February 06, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2019 financial results on Thursday,...
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will...
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
October 31, 2019 07:30 ET
|
Repligen Corporation
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year 2019, representing 31%-32%...